129 related articles for article (PubMed ID: 17726264)
21. Comparison of the peptide structural requirements for high affinity interaction with bombesin receptors.
Lin JT; Coy DH; Mantey SA; Jensen RT
Eur J Pharmacol; 1995 Dec; 294(1):55-69. PubMed ID: 8788416
[TBL] [Abstract][Full Text] [Related]
22. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.
Reubi C; Gugger M; Waser B
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):855-62. PubMed ID: 12111125
[TBL] [Abstract][Full Text] [Related]
23. Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers.
Sun B; Halmos G; Schally AV; Wang X; Martinez M
Prostate; 2000 Mar; 42(4):295-303. PubMed ID: 10679759
[TBL] [Abstract][Full Text] [Related]
24. Bombesin receptor antagonists may be preferable to agonists for tumor targeting.
Cescato R; Maina T; Nock B; Nikolopoulou A; Charalambidis D; Piccand V; Reubi JC
J Nucl Med; 2008 Feb; 49(2):318-26. PubMed ID: 18199616
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent and selective peptide agonists at the GRP-preferring bombesin receptor (BB2).
Darker JG; Brough SJ; Heath J; Smart D
J Pept Sci; 2001 Nov; 7(11):598-605. PubMed ID: 11763364
[TBL] [Abstract][Full Text] [Related]
26. Molecular cloning and characterization of avian bombesin-like peptide receptors: new tools for investigating molecular basis for ligand selectivity.
Iwabuchi M; Ui-Tei K; Yamada K; Matsuda Y; Sakai Y; Tanaka K; Ohki-Hamazaki H
Br J Pharmacol; 2003 Jun; 139(3):555-66. PubMed ID: 12788815
[TBL] [Abstract][Full Text] [Related]
27. Early over-expression of GRP receptors in prostatic carcinogenesis.
Körner M; Waser B; Rehmann R; Reubi JC
Prostate; 2014 Feb; 74(2):217-24. PubMed ID: 24150752
[TBL] [Abstract][Full Text] [Related]
28. Activation of neuromedin B-preferring bombesin receptors on rat glioblastoma C-6 cells increases cellular Ca2+ and phosphoinositides.
Wang LH; Battey JF; Wada E; Lin JT; Mantey S; Coy DH; Jensen RT
Biochem J; 1992 Sep; 286 ( Pt 2)(Pt 2):641-8. PubMed ID: 1326946
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of a new bombesin analog for imaging of gastrin-releasing peptide receptors.
Shirmardi SP; Gandomkar M; Maragheh MG; Shamsaei M
Cancer Biother Radiopharm; 2011 Jun; 26(3):309-16. PubMed ID: 21711115
[TBL] [Abstract][Full Text] [Related]
30. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells.
Reile H; Armatis PE; Schally AV
Prostate; 1994 Jul; 25(1):29-38. PubMed ID: 8022709
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo application of radiolabeled gastrin-releasing peptide receptor ligands in breast cancer.
Dalm SU; Martens JW; Sieuwerts AM; van Deurzen CH; Koelewijn SJ; de Blois E; Maina T; Nock BA; Brunel L; Fehrentz JA; Martinez J; de Jong M; Melis M
J Nucl Med; 2015 May; 56(5):752-7. PubMed ID: 25791989
[TBL] [Abstract][Full Text] [Related]
32. Peptide structural requirements for antagonism differ between the two mammalian bombesin receptor subtypes.
Lin JT; Coy DH; Mantey SA; Jensen RT
J Pharmacol Exp Ther; 1995 Oct; 275(1):285-95. PubMed ID: 7562561
[TBL] [Abstract][Full Text] [Related]
33. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical detection of bombesin receptor subtypes GRP-R and BRS-3 in human tumors using novel antipeptide antibodies.
Schulz S; Röcken C; Schulz S
Virchows Arch; 2006 Oct; 449(4):421-7. PubMed ID: 16967266
[TBL] [Abstract][Full Text] [Related]
35. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
[TBL] [Abstract][Full Text] [Related]
38. microPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts.
Chen X; Park R; Hou Y; Tohme M; Shahinian AH; Bading JR; Conti PS
J Nucl Med; 2004 Aug; 45(8):1390-7. PubMed ID: 15299066
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of growth of experimental human and hamster pancreatic cancers in vivo by a targeted cytotoxic bombesin analog.
Szepeshazi K; Schally AV; Nagy A; Halmos G
Pancreas; 2005 Oct; 31(3):275-82. PubMed ID: 16163060
[TBL] [Abstract][Full Text] [Related]
40. Potent bombesin-like peptides for GRP-receptor targeting of tumors with 99mTc: a preclinical study.
Nock BA; Nikolopoulou A; Galanis A; Cordopatis P; Waser B; Reubi JC; Maina T
J Med Chem; 2005 Jan; 48(1):100-10. PubMed ID: 15634004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
